Literature DB >> 26658302

DOOR/RADAR: A Gateway Into the Unknown?

Patrick Peter John Phillips1, Tim Peter Morris2, Ann Sarah Walker1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26658302     DOI： 10.1093/cid/civ1002

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  Reply to Phillips, Morris, and Walker.

Authors:  Scott Evans; Dean Follmann; David Schoenfeld; Vance G Fowler; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

2.  Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Authors:  Daniele Roberto Giacobbe; Alessio Signori; Mario Tumbarello; Riccardo Ungaro; Giovanni Sarteschi; Elisa Furfaro; Malgorzata Mikulska; Maurizio Sanguinetti; Brunella Posteraro; Angela Raffaella Losito; Gennaro De Pascale; Valerio Del Bono; Claudio Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-30       Impact factor: 3.267

3.  Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials.

Authors:  S Kim; J A Seddon; A J Garcia-Prats; G Montepiedra
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 2.373

4.  Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Authors:  Sarah B Doernberg; Thuy Tien Tram Tran; Steven Y C Tong; Mical Paul; Dafna Yahav; Joshua S Davis; Leonard Leibovici; Helen W Boucher; G Ralph Corey; Sara E Cosgrove; Henry F Chambers; Vance G Fowler; Scott R Evans; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

5.  Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.

Authors:  Sachiko Miyahara; Ritesh Ramchandani; Soyeon Kim; Scott R Evans; Amita Gupta; Susan Swindells; Richard E Chaisson; Grace Montepiedra
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

6.  Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net.

Authors:  Jean-François Timsit; Marlieke E A de Kraker; Harriet Sommer; Emmanuel Weiss; Esther Bettiol; Martin Wolkewitz; Stavros Nikolakopoulos; David Wilson; Stephan Harbarth
Journal:  Intensive Care Med       Date:  2017-05-02       Impact factor: 17.440

7.  Rethinking non-inferiority: a practical trial design for optimising treatment duration.

Authors:  Matteo Quartagno; A Sarah Walker; James R Carpenter; Patrick Pj Phillips; Mahesh Kb Parmar
Journal:  Clin Trials       Date:  2018-06-05       Impact factor: 2.486

8.  Optimising trial designs to identify appropriate antibiotic treatment durations.

Authors:  Koen B Pouwels; Mo Yin; Christopher C Butler; Ben S Cooper; Sarah Wordsworth; A Sarah Walker; Julie V Robotham
Journal:  BMC Med       Date:  2019-06-21       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.